Artax Biopharma is a clinical-stage biotechnology company transforming the treatment of T Cell-driven autoimmune diseases. Our first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options. Our lead program AX-158 will deliver results in a Phase 2a Proof of Concept study in psoriasis later in 2024. In contrast to agents targeting individual cytokines, we believe our approach will allow us to address a broad spectrum of patients. By having the potential to impact multiple cytokines, we hope to address areas of high unmet need beyond where targeted therapies have achieved success.